Skip to content
FY'25FY'24FY'23FY'22
Profitability
Gross margin77.7%-1.9pp79.7%+1.7pp78%+2.0pp76%+1.5pp
Returns
Return on invested capital6.6%-1.4pp8%+4.2pp3.8%-0.8pp4.6%+6.8pp
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.4×0.0×0.3×0.0×
Liquidity
Current ratio5.2×-0.1×5.3×+2.8×2.5×-2.2×4.7×+0.5×
Leverage
Debt-to-equity0.1×+0.1×-0.1×0.1×+0.1×0.0×
Net debt / EBITDA-1.2×+0.3×-1.6×-0.8×-0.7×+1.8×-2.5×+18.6×
Per Share
Book value per share$30.84+7.2%$28.76+11.3%$25.84+6.1%$24.36+4.4%
Valuation
Market capitalization$11.42B-8.9%$12.53B-31.0%$18.16B-5.6%$19.23B+18.6%
Price / sales3.5×-0.8×4.4×-3.1×7.5×-1.7×9.2×+0.4×
Price / book1.9×-0.3×2.2×-1.5×3.7×-0.5×4.2×+0.4×
EV / EBITDA20×0.0×20×-41.8×61.9×-5.3×67.2×-543×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BioMarin Pharmaceuticals's profit margins?
BioMarin Pharmaceuticals (BMRN) runs a 76.5% gross margin and a 19.9% operating margin, with a 16.8% net margin.
Where do BioMarin Pharmaceuticals's ratios come from?
Every ratio is computed from BioMarin Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.